Clinical Trial Update: Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 trial of ibrutinib in patients with follicular lymphoma who did not achieve a complete response to initial chemoimmunotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Follicular Lymphoma, Follicular Lymphoma, Grade 1 | EARLY_Phase 1 | Status: TERMINATED